Blog
RSS FeedPosted by Michael Wonder on 22 Oct 2016
France's High Authority of Health is in favour of delisting Alzheimer's disease drugs
22 October 2016 - The Transparency Committee, responsible for evaluating medicinal products within the High Authority of Health recommended against ...
Posted by Michael Wonder on 13 Oct 2016
Agenda for 19 October Transparency Commission meeting
12 October 2016 - HAS has published the agenda for the next scheduled Transparency Commission meeting. ...
Posted by Michael Wonder on 28 Sep 2016
Agenda for the 5 October 2016 TC meeting
28 September 2016 - HAS has posted the agenda for the next scheduled TC meeting. ...
Posted by Michael Wonder on 27 Sep 2016
TC opinion on Lyxumia finally published
26 September 2016 - The Transparency Commission has published its opinion on Sanofi's GLP-1 analogue. ...
Posted by Michael Wonder on 19 Sep 2016
Agenda for 21 September 2016 TC meeting
19 September 2016 - The Transparency Commission will consider the reimbursement of a number of new medicines and blood products. ...
Posted by Michael Wonder on 30 Aug 2016
Agenda for the 7 September 2016 TC meeting
30 August 2016 - The Transparency Commission will reconvene early next month after the summer break to review a few new ...
Posted by Michael Wonder on 16 Jul 2016
Agenda for the 20 July 2016 TC meeting
15 July 2016 - The Transparency Commission will consider the reimbursement of new medicines and blood products. ...
Posted by Michael Wonder on 30 Jun 2016
Agenda for the 6 July 2016 TC meeting
30 June 2016 - The Transparency Commission will consider the reimbursement of new medicines and blood products. ...
Posted by Michael Wonder on 23 Jun 2016
Agenda for the 29 June 2016 TC meeting
23 June 2016 - The Transparency Commission will consider the reimbursement of migalastat hydrochloride (Galafold), lignocaine hydrochloride with phenylephrine hydrochloride and ...
Posted by Michael Wonder on 16 Jun 2016
Agenda for the 22 June 2016 TC meeting
16 June 2016 - The Transparency Commission will consider the reimbursement of glatiramer acetate (Copaxone), ruxolitinib phosphate (Jakavi), clobazam (Likozam) and ...
Posted by Michael Wonder on 02 Jun 2016
Agenda for the 8 June 2016 TC meeting
1 June 2016 - The Transparency Commission will consider the (continued) reimbursement of dexketoprofen with tramadol hydrochloride (Skudexum), empagliflozin (Jardiance), plasma ...
Posted by Michael Wonder on 21 May 2016
Agenda for the 25 May 2016 TC meeting
22 May 2016 - The Transparency Commission will consider the (continued) reimbursement of voriconazole (Vfend), belatacept (Nulojix), bevacizumab (Avastin), bicalutamide (Casodex), ...
Posted by Michael Wonder on 05 May 2016
Agenda for the 11 May 2016 TC meeting
5 May 2016 - The Transparency Commission will consider the reimbursement of golimumab (Simponi), metyrapone (Metyrapone HRA Pharma) and tiotropium bromide ...
Posted by Michael Wonder on 13 Apr 2016
Agenda for the 20 April 2016 TC meeting
13 April 2016 - The Transparency Commission will consider the reimbursement of Wakix (pitolisant), Busilvex (busulphan), Cosentyx (secukinumab), Anoro Ellipta (vilanterol ...
Posted by Michael Wonder on 12 Apr 2016
Agenda for the 13 April 2016 TC meeting
12 April 2016 - The Transparency Commission will consider the reimbursement of Praxbind (idarucizumab) and Xalatan (latanoprost). The Commission will also ...